NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
55700-0209-20 | 55700-0209 | Prednisone | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan 16, 2015 | Oct 11, 2019 | In Use |
60505-6132-07 | 60505-6132 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan 4, 2017 | In Use | |
63629-2613-01 | 63629-2613 | Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 2.5 mg/1 | Hormonal Therapy | Progestin | Oral | Mar 7, 2005 | In Use | ||
68788-7961-03 | 68788-7961 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Jul 16, 2021 | In Use | ||
70121-1609-05 | 70121-1609 | Methylprednisolone acetate | Methylprednisolone acetate | 40.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-articular, Intralesional, Intramuscular, Intrasynovial, Soft Tissue | Nov 10, 2023 | In Use | |
70121-1610-05 | 70121-1610 | Methylprednisolone acetate | Methylprednisolone acetate | 80.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-articular, Intra-articular, Intralesional, Intramuscular, Intrasynovial, Soft Tissue | Nov 10, 2023 | In Use | |
70121-1754-07 | 70121-1754 | Bevacizumab-maly | ALYMSYS | 100.0 mg/4mL | Immunotherapy | Monoclonal Antibody | VEGF | Intravenous | Apr 15, 2022 | In Use | |
70121-1755-07 | 70121-1755 | bevacizumab-maly | ALYMSYS | 400.0 mg/16mL | Immunotherapy | Monoclonal Antibody | VEGF | Intravenous | Apr 15, 2022 | In Use | |
70377-0010-11 | 70377-0010 | Everolimus | EVEROLIMUS | 2.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 8, 2023 | In Use | |
70377-0011-11 | 70377-0011 | Everolimus | EVEROLIMUS | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 8, 2023 | In Use | |
70518-2368-02 | 70518-2368 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Apr 13, 2022 | In Use | ||
70934-0634-84 | 70934-0634 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 13, 2021 | Jan 31, 2025 | In Use |
70934-0809-87 | 70934-0809 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Apr 22, 2021 | Feb 28, 2025 | In Use |
70934-0831-12 | 70934-0831 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Mar 24, 2021 | In Use | |
71335-2477-02 | 71335-2477 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Sep 3, 2024 | In Use | ||
16729-0545-63 | 16729-0545 | CARMUSTINE | CARMUSTINE | Chemotherapy | Alkylating Agent | Nitrosourea | Aug 18, 2022 | In Use | |||
72162-1878-01 | 72162-1878 | Dronabinol | Dronabinol | 2.5 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | Mar 30, 2023 | In Use | |
82868-0038-90 | 82868-0038 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Jan 18, 2024 | In Use | ||
82950-0001-20 | 82950-0001 | TOVORAFENIB | OJEMDA | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BRAF, CRAF | Oral | Apr 30, 2024 | In Use | |
83008-0026-65 | 83008-0026 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct 3, 2023 | In Use | |
42291-0374-90 | 42291-0374 | Letrozole | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Jan 5, 2015 | In Use | ||
16571-0819-41 | 16571-0819 | Temozolomide | TEMOZOLOMIDE | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct 4, 2022 | In Use | |
45963-0734-74 | 45963-0734 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Sep 1, 2014 | Jul 31, 2017 | In Use |
46708-0678-16 | 46708-0678 | Docetaxel | Docetaxel | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Feb 28, 2023 | In Use | |
47335-0485-08 | 47335-0485 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Dec 15, 2014 | In Use |
Found 11120 results — Export these results